AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04418934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemanext One
Description: Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 56 days at 1-6°C.
Study NCT03312153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neem
Description: A natural irrigant solution act as anti-inflammatory and anti bacterial
Study NCT03312153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% sodium hypochlorite
Description: anti bacterial root canal irrigant solution
Study NCT01152775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: This group of patients will be exposed to multimedia
Description: This group of patients will be exposed to multimedia
Study NCT01152775 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Media
Description: This group will not be exposed to multimedia
Study NCT00838682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole sodium IV
Description: Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
Study NCT00838682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
Study NCT01126827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy
Description: 12 weekly group therapy sessions
Study NCT02472652 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abilify Maintena
Description: For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
Study NCT03895164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced NE
Description: Standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
Study NCT03895164 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard NE
Description: Standard nutrition education package from primary health care
Study NCT03464279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge using Behavioral Economic Interventions
Study NCT03464279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practices to Reduce Health System Antibiotic Prescription
Study NCT02891538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).\*
Study NCT00800202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks
Study NCT00800202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC6 iv every 3 weeks for 6 cycles
Study NCT00800202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg/day po
Study NCT00800202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200mg/m2 iv every 3 weeks for 6 cycles
Study NCT01768832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill
Study NCT01768832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tango
Study NCT01768832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Study NCT02376621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PronovaPure 150:500 triglycerides
Description: Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
Study NCT02376621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-048
Description: Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
Study NCT02376621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-037
Description: Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
Study NCT02376621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PronovaPure 500:200 TG
Description: Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
Study NCT02376621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-047
Description: Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
Study NCT01490879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® Low Dose
Description: Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
Study NCT03852238 — intervention group
Intervention type: OTHER
Intervention: Blood test and self-administrated questionnaires
Study NCT02985762 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EXPAREL
Study NCT03590340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Study NCT03590340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is 0.9% sodium chloride
Study NCT03590340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (for CHMI)
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
Study NCT03590340 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (for CHMI)
Description: Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
Study NCT01100255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine infusion
Description: 0.5mg/kg IV over 40 minutes
Study NCT01100255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline infusion
Study NCT01490879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® Medium Dose
Description: Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
Study NCT00180479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT00180479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT04108130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Education
Description: Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
Study NCT04108130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization
Description: PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
Study NCT04108130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualization of Neuromuscular Blockade
Description: Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
Study NCT01490879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® High Dose
Description: Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
Study NCT01490879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nexagon® vehicle
Description: Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
Study NCT01847781 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Study NCT01085630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01085630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation
Study NCT03119675 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GoCheck Kids (iOS)
Description: Photorefraction method is used to screen amblyopia risk factors.
Study NCT04108130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative Incentive Spirometry
Description: Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
Study NCT04108130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Ambulation
Description: Participants will be encouraged to adhere to prescription of early ambulation.
Study NCT01945905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intramural
Description: Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
Study NCT01945905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extramural
Description: In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
Study NCT04445857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally
Description: coadministration of calcitonin intrathecally and a single-shot hyperbaric bupivacaine
Study NCT04445857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously
Description: coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine
Study NCT04445857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (NS)
Description: coadministration of normal saline and a single-shot hyperbaric bupivacaine
Study NCT02736825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System with standard transducer
Description: Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time
Study NCT02736825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System with prototype 2 simulines transducer
Description: Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously
Study NCT00650195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone Tablets 10 mg
Description: 10mg, single dose fasting
Study NCT00650195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaroloxyn® Tablets 10 mg
Description: 10mg, single dose fasting
Study NCT02380443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
Study NCT02380443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
Study NCT00813852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training, IMT
Description: Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
Study NCT00985725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
Study NCT00985725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: oral, once daily
Study NCT03517592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR
Description: The EMDR SUD Protocol consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol and a further specific protocol for SUD that is focused on the concept of addiction memory.
Study NCT03517592 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
Study NCT01548430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP4000
Study NCT01548430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01925625 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Early CDT Lung blood test
Description: The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
Study NCT03756584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta-burst stimulation
Description: iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
Study NCT03756584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation
Description: iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
Study NCT04536259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Default
Description: The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person.
Study NCT00105235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
Study NCT00105235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Oral immunosuppressant
Study NCT00105235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Oral immunosuppressant
Study NCT00105235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral immunosuppressant
Study NCT00105235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplant
Description: Occurs at study entry
Study NCT00105235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal
Description: Beginning no earlier than Year 1
Study NCT00530803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Cream
Description: 60 minutes x1
Study NCT00530803 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Synera Patch
Description: 20 minutes x1
Study NCT02405260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP399 400 mg
Description: once daily
Study NCT02405260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP399 800 mg
Description: once daily
Study NCT04536259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Default
Description: The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video.
Study NCT04536259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Choice
Description: The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation.
Study NCT04168476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interscapular muscle release or scapular mobilization technique as described by Travell and Simons.
Description: Patient is sidelying with the testing side up. The auditor stands in front of the patient, reaches over the patient's shoulder to grasp the upper portion of the vertebral border of the scapula, and the other arm reaches under the patient's humerus to grasp the lower portion of the vertebral border of the scapula.~The auditor then slowly moves the scapula into elevation/depression, internal/external rotation/abduction and adduction.~To standardize the technique and be able to reproduce it in each participant, a set of 10 repetitions for each movement was performed in the same order.
Study NCT04168476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Calcaneus abduction and adduction mobilization technique
Description: Abduction and adduction mobilization of the calcaneus is carried out in the opposite side of the upper extremity measured.
Study NCT00778947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic Synergy Dissecting Hook (Harmonic Scalpel)
Description: Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
Study NCT00778947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery Diathermy
Description: Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.